FcγRIIa
FCGR2AproteinFc receptor on platelets mediating immune-complex-driven platelet aggregation and thrombotic amplification.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencehigh
RationaleIgG receptor amplifying platelet activation and immune complex signaling.
Also acts inVascular inflammation
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000143226
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I74
C — confounder / Type-II62
A — assay feasibility68
E — evidence strength29
T1DI (composite)11
Specificity differential (R−C)+11.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(3)
- Variation in platelet expression of FcγRIIa after myocardial infarction.Journal of thrombosis and thrombolysis · 2019 · PMID 30968301 · doi
- Mucor circinelloides induces platelet aggregation through integrin αIIbβ3 and FcγRIIA.Platelets · 2018 · PMID 29297721 · doi
- Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA.Blood · 2001 · PMID 11588041 · doi